Global Neurodegenerative Drugs Market Research Report 2019

Table of Contents

Executive Summary

1 Neurodegenerative Drugs Market Overview

• 1.1 Product Overview and Scope of Neurodegenerative Drugs
• 1.2 Neurodegenerative Drugs Segment by Type
  • 1.2.1 Global Neurodegenerative Drugs Production Growth Rate Comparison by Type (2014-2025)
  • 1.2.2 NMDA
  • 1.2.3 SSRIs
  • 1.2.4 Dopamine Inhibitors
• 1.3 Neurodegenerative Drugs Segment by Application
  • 1.3.1 Neurodegenerative Drugs Consumption Comparison by Application (2014-2025)
  • 1.3.2 Hospital
  • 1.3.3 Research
• 1.4 Global Neurodegenerative Drugs Market by Region
  • 1.4.1 Global Neurodegenerative Drugs Market Size Region
  • 1.4.2 North America Status and Prospect (2014-2025)
  • 1.4.3 Europe Status and Prospect (2014-2025)
  • 1.4.4 China Status and Prospect (2014-2025)
  • 1.4.5 Japan Status and Prospect (2014-2025)
• 1.5 Global Neurodegenerative Drugs Market Size
  • 1.5.1 Global Neurodegenerative Drugs Revenue (2014-2025)
  • 1.5.2 Global Neurodegenerative Drugs Production (2014-2025)

2 Global Neurodegenerative Drugs Market Competition by Manufacturers

• 2.1 Global Neurodegenerative Drugs Production Market Share by Manufacturers (2014-2019)
• 2.2 Global Neurodegenerative Drugs Revenue Share by Manufacturers (2014-2019)
• 2.3 Global Neurodegenerative Drugs Average Price by Manufacturers (2014-2019)
• 2.4 Manufacturers Neurodegenerative Drugs Production Sites, Area Served, Product Types
• 2.5 Neurodegenerative Drugs Market Competitive Situation and Trends
  • 2.5.1 Neurodegenerative Drugs Market Concentration Rate
  • 2.5.2 Neurodegenerative Drugs Market Share of Top 3 and Top 5 Manufacturers
  • 2.5.3 Mergers & Acquisitions, Expansion

3 Global Neurodegenerative Drugs Production Market Share by Regions

• 3.1 Global Neurodegenerative Drugs Production Market Share by Regions
• 3.2 Global Neurodegenerative Drugs Revenue Market Share by Regions (2014-2019)
• 3.3 Global Neurodegenerative Drugs Production, Revenue, Price and Gross Margin (2014-2019)
• 3.4 North America Neurodegenerative Drugs Production
  • 3.4.1 North America Neurodegenerative Drugs Production Growth Rate (2014-2019)
  • 3.4.2 North America Neurodegenerative Drugs Production, Revenue, Price and Gross Margin (2014-2019)
• 3.5 Europe Neurodegenerative Drugs Production
  • 3.5.1 Europe Neurodegenerative Drugs Production Growth Rate (2014-2019)
  • 3.5.2 Europe Neurodegenerative Drugs Production, Revenue, Price and Gross Margin (2014-2019)
• 3.6 China Neurodegenerative Drugs Production (2014-2019)
  • 3.6.1 China Neurodegenerative Drugs Production Growth Rate (2014-2019)
  • 3.6.2 China Neurodegenerative Drugs Production, Revenue, Price and Gross Margin (2014-2019)
• 3.7 Japan Neurodegenerative Drugs Production (2014-2019)
  • 3.7.1 Japan Neurodegenerative Drugs Production Growth Rate (2014-2019)
  • 3.7.2 Japan Neurodegenerative Drugs Production, Revenue, Price and Gross Margin (2014-2019)

4 Global Neurodegenerative Drugs Consumption by Regions

• 4.1 Global Neurodegenerative Drugs Consumption by Regions
• 4.2 North America Neurodegenerative Drugs Consumption (2014-2019)
• 4.3 Europe Neurodegenerative Drugs Consumption (2014-2019)
• 4.4 China Neurodegenerative Drugs Consumption (2014-2019)
• 4.5 Japan Neurodegenerative Drugs Consumption (2014-2019)

5 Global Neurodegenerative Drugs Production, Revenue, Price Trend by Type

• 5.1 Global Neurodegenerative Drugs Production Market Share by Type (2014-2019)
• 5.2 Global Neurodegenerative Drugs Revenue Market Share by Type (2014-2019)
• 5.3 Global Neurodegenerative Drugs Price by Type (2014-2019)
• 5.4 Global Neurodegenerative Drugs Production Growth by Type (2014-2019)

6 Global Neurodegenerative Drugs Market Analysis by Applications

• 6.1 Global Neurodegenerative Drugs Consumption Market Share by Application (2014-2019)
• 6.2 Global Neurodegenerative Drugs Consumption Growth Rate by Application (2014-2019)

7 Company Profiles and Key Figures in Neurodegenerative Drugs Business

• 7.1 Novartis
  • 7.1.1 Novartis Neurodegenerative Drugs Production Sites and Area Served
  • 7.1.2 Neurodegenerative Drugs Product Introduction, Application and Specification
  • 7.1.3 Novartis Neurodegenerative Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.1.4 Main Business and Markets Served
• 7.2 Pfizer
  • 7.2.1 Pfizer Neurodegenerative Drugs Production Sites and Area Served
  • 7.2.2 Neurodegenerative Drugs Product Introduction, Application and Specification
  • 7.2.3 Pfizer Neurodegenerative Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.2.4 Main Business and Markets Served
• 7.3 Merck Serono
  • 7.3.1 Merck Serono Neurodegenerative Drugs Production Sites and Area Served
  • 7.3.2 Neurodegenerative Drugs Product Introduction, Application and Specification
  • 7.3.3 Merck Serono Neurodegenerative Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.3.4 Main Business and Markets Served
• 7.4 Biogen Idec
  • 7.4.1 Biogen Idec Neurodegenerative Drugs Production Sites and Area Served
  • 7.4.2 Neurodegenerative Drugs Product Introduction, Application and Specification
  • 7.4.3 Biogen Idec Neurodegenerative Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.4.4 Main Business and Markets Served
• 7.5 TEVA Pharmaceuticals
  • 7.5.1 TEVA Pharmaceuticals Neurodegenerative Drugs Production Sites and Area Served
  • 7.5.2 Neurodegenerative Drugs Product Introduction, Application and Specification
  • 7.5.3 TEVA Pharmaceuticals Neurodegenerative Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.5.4 Main Business and Markets Served
• 7.6 UCB
  • 7.6.1 UCB Neurodegenerative Drugs Production Sites and Area Served
  • 7.6.2 Neurodegenerative Drugs Product Introduction, Application and Specification
  • 7.6.3 UCB Neurodegenerative Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.6.4 Main Business and Markets Served
• 7.7 Boehringer Ingelheim
  • 7.7.1 Boehringer Ingelheim Neurodegenerative Drugs Production Sites and Area Served
  • 7.7.2 Neurodegenerative Drugs Product Introduction, Application and Specification
  • 7.7.3 Boehringer Ingelheim Neurodegenerative Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.7.4 Main Business and Markets Served
• 7.8 Sanofi
  • 7.8.1 Sanofi Neurodegenerative Drugs Production Sites and Area Served
  • 7.8.2 Neurodegenerative Drugs Product Introduction, Application and Specification
  • 7.8.3 Sanofi Neurodegenerative Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.8.4 Main Business and Markets Served
• 7.9 GlaxoSmithKline
  • 7.9.1 GlaxoSmithKline Neurodegenerative Drugs Production Sites and Area Served
  • 7.9.2 Neurodegenerative Drugs Product Introduction, Application and Specification
  • 7.9.3 GlaxoSmithKline Neurodegenerative Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.9.4 Main Business and Markets Served

8 Neurodegenerative Drugs Manufacturing Cost Analysis

• 8.1 Neurodegenerative Drugs Key Raw Materials Analysis
  • 8.1.1 Key Raw Materials
  • 8.1.2 Price Trend of Key Raw Materials
  • 8.1.3 Key Suppliers of Raw Materials
• 8.2 Proportion of Manufacturing Cost Structure
• 8.3 Manufacturing Process Analysis of Neurodegenerative Drugs
• 8.4 Neurodegenerative Drugs Industrial Chain Analysis

9 Marketing Channel, Distributors and Customers

• 9.1 Marketing Channel
  • 9.1.1 Direct Marketing
  • 9.1.2 Indirect Marketing
• 9.2 Neurodegenerative Drugs Distributors List
• 9.3 Neurodegenerative Drugs Customers

10 Market Dynamics

• 10.1 Market Trends
• 10.2 Opportunities
• 10.3 Market Drivers
• 10.4 Challenges
• 10.5 Influence Factors

11 Global Neurodegenerative Drugs Market Forecast

• 11.1 Global Neurodegenerative Drugs Production, Revenue Forecast
  • 11.1.1 Global Neurodegenerative Drugs Production Growth Rate Forecast (2019-2025)
  • 11.1.2 Global Neurodegenerative Drugs Revenue and Growth Rate Forecast (2019-2025)
  • 11.1.3 Global Neurodegenerative Drugs Price and Trend Forecast (2019-2025)
• 11.2 Global Neurodegenerative Drugs Production Forecast by Regions (2019-2025)
  • 11.2.1 North America Neurodegenerative Drugs Production, Revenue Forecast (2019-2025)
  • 11.2.2 Europe Neurodegenerative Drugs Production, Revenue Forecast (2019-2025)
  • 11.2.3 China Neurodegenerative Drugs Production, Revenue Forecast (2019-2025)
  • 11.2.4 Japan Neurodegenerative Drugs Production, Revenue Forecast (2019-2025)
• 11.3 Global Neurodegenerative Drugs Consumption Forecast by Regions (2019-2025)
  • 11.3.1 North America Neurodegenerative Drugs Consumption Forecast (2019-2025)
  • 11.3.2 Europe Neurodegenerative Drugs Consumption Forecast (2019-2025)
  • 11.3.3 China Neurodegenerative Drugs Consumption Forecast (2019-2025)
  • 11.3.4 Japan Neurodegenerative Drugs Consumption Forecast (2019-2025)
• 11.4 Global Neurodegenerative Drugs Production, Revenue and Price Forecast by Type (2019-2025)
• 11.5 Global Neurodegenerative Drugs Consumption Forecast by Application (2019-2025)

12 Research Findings and Conclusion

13 Methodology and Data Source

• 13.1 Methodology/Research Approach
  • 13.1.1 Research Programs/Design
  • 13.1.2 Market Size Estimation
  • 13.1.3 Market Breakdown and Data Triangulation
• 13.2 Data Source
  • 13.2.1 Secondary Sources
  • 13.2.2 Primary Sources
• 13.3 Author List